ONCOTICE

This brand name is authorized in Australia, Austria, Canada, Cyprus, Israel, New Zealand, Poland, Spain, Turkey, UK.

Active ingredients

The drug ONCOTICE contains one active pharmaceutical ingredient (API):

1	Bacillus Calmette-Guerin (BCG strain Tice) UNII XZQ806VFEO - MYCOBACTERIUM BOVIS
	BCG vaccine is an immunostimulating agent. It has anti-tumor activity, but the exact mechanism of action is not known.
	Read more about BCG vaccine

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
ONCOTICE Powder for instillation fluid for intravesical use	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
L03AX03	BCG vaccine	L Antineoplastic and immunomodulating agents → L03 Immunostimulants → L03A Immunostimulants → L03AX Other immunostimulants
Discover more medicines within L03AX03

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	1131M, 5902P
CA	Health Products and Food Branch	02153513
ES	Centro de información online de medicamentos de la AEMPS	61377
GB	Medicines & Healthcare Products Regulatory Agency	80691
IL	מִשְׂרַד הַבְּרִיאוּת	8564
NZ	Medicines and Medical Devices Safety Authority	6143
PL	Rejestru Produktów Leczniczych	100195800
TR	İlaç ve Tıbbi Cihaz Kurumu	8699636790403